Recombinant soluble type I interferon receptor exerts antiviral activity by inducing proteins related to autophagy
The soluble type I IFN receptor (sIFNAR2) is produced by alternative splicing and is present in body fluids. Although it can modulate IFN-ß activity, its biological role remains unknown. An in-silico study was conducted to compare the structure of recombinant human soluble IFNAR2 (r-sIFNAR2) with it...
Gespeichert in:
Veröffentlicht in: | Biomedicine & pharmacotherapy 2024-12, Vol.181, p.117678, Article 117678 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | 117678 |
container_title | Biomedicine & pharmacotherapy |
container_volume | 181 |
creator | Aliaga-Gaspar, Pablo Brichette-Mieg, Isabel Fernández-Arjona, MdM Rodríguez-Bada, José Luis López-Moreno, Yolanda Serrano-Castro, Pedro Fernández-Fernández, Oscar Ciano-Petersen, Nicolás Lundahl Oliver-Martos, Begoña |
description | The soluble type I IFN receptor (sIFNAR2) is produced by alternative splicing and is present in body fluids. Although it can modulate IFN-ß activity, its biological role remains unknown.
An in-silico study was conducted to compare the structure of recombinant human soluble IFNAR2 (r-sIFNAR2) with its native form. The antiviral activity of r-sIFNAR2, produced in BL21-bacteria and CHO cells, was tested using a cytopathic effect assay including appropriate controls. Viability and toxicity were assessed by MTT assays. Proteomic analysis using mass spectrometry was conducted in the A549/EMCV bioassay to elucidate the mechanism of action, and then it was validated by Western blot.
The BL21-sIFNAR2 had a sequence identity of 83.6 % with the native form, showing variations only in terminal regions. BL21-sIFNAR2 and CHO-sIFNAR2 showed significantly higher percentage of cell viability compared to the viral control, similar to IFN-ß. Cell viability with BL21-sIFNAR2 was comparable to the cell control across all tested concentrations.
Proteomic analysis revealed an up regulation of pathways related with autophagy (macroautophagy, autophagy, pexophagy, and mitophagy) with an SQSTM1 overexpression that was then confirmed by Western Blot, especially after virus infection. However, pathways related to interferon signaling, and antiviral mechanisms mediated by IFN-stimulated genes were down-regulated.
r-sIFNAR2 exhibits significant antiviral activity regardless of the expression system used for its production and good safety profile, suggesting its use as a potential antiviral drug. Proteins related to autophagy are involved in the protection from the virus. This study highlights the biological relevance of soluble cytokine receptors as effectors so far overlooked.
[Display omitted]
•Soluble type I IFN can modulate endogenous and systemically administered IFNß, but its role is unknown.•A recombinant soluble type I IFN receptor, cloned in two systems, showed strong antiviral activity and a good safety profile.•Its mechanism of action is related to autophagy activation.•Recombinant sIFNAR2 could be of relevance for the treatment of viral diseases. |
doi_str_mv | 10.1016/j.biopha.2024.117678 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3132140666</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0753332224015646</els_id><sourcerecordid>3132140666</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1564-2bd54e4fdbe49fc5bd41cd9b769152e01bcb01ed8f239394c059eef73db6798d3</originalsourceid><addsrcrecordid>eNp9kEtv1DAURi1ERYfCP0DISzYZ7Pg13iChipZKlZBQWVt-3BSPMnGwnYr8ezxKYcnq3sX57uMg9I6SPSVUfjzuXUzzT7vvSc_3lCqpDi_QjmpBOkmIeol2RAnWMdb3l-h1KUdCiJDs8ApdMi2UYpLvUP4OPp1cnOxUcUnj4kbAdZ0B3-E4VcgD5DThDB7mmjKG35BrwY2OTzHbEVt_7uqK3doCYfFxesRzThXiVFputBUCrgnbpZ7PfVzfoIvBjgXePtcr9OPmy8P11-7-2-3d9ef7zlMhede7IDjwITjgevDCBU590E5JTUUPhDrvCIVwGHqmmeaeCA0wKBacVPoQ2BX6sM1t1_xaoFRzisXDONoJ0lIMo6ynnEgpG8o31OdUSobBzDmebF4NJeZs2xzNZtucbZvNdou9f96wuBOEf6G_ehvwaQOg_fkUIZviI0weQmxGqwkp_n_DH18dlYI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3132140666</pqid></control><display><type>article</type><title>Recombinant soluble type I interferon receptor exerts antiviral activity by inducing proteins related to autophagy</title><source>Access via ScienceDirect (Elsevier)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Aliaga-Gaspar, Pablo ; Brichette-Mieg, Isabel ; Fernández-Arjona, MdM ; Rodríguez-Bada, José Luis ; López-Moreno, Yolanda ; Serrano-Castro, Pedro ; Fernández-Fernández, Oscar ; Ciano-Petersen, Nicolás Lundahl ; Oliver-Martos, Begoña</creator><creatorcontrib>Aliaga-Gaspar, Pablo ; Brichette-Mieg, Isabel ; Fernández-Arjona, MdM ; Rodríguez-Bada, José Luis ; López-Moreno, Yolanda ; Serrano-Castro, Pedro ; Fernández-Fernández, Oscar ; Ciano-Petersen, Nicolás Lundahl ; Oliver-Martos, Begoña</creatorcontrib><description>The soluble type I IFN receptor (sIFNAR2) is produced by alternative splicing and is present in body fluids. Although it can modulate IFN-ß activity, its biological role remains unknown.
An in-silico study was conducted to compare the structure of recombinant human soluble IFNAR2 (r-sIFNAR2) with its native form. The antiviral activity of r-sIFNAR2, produced in BL21-bacteria and CHO cells, was tested using a cytopathic effect assay including appropriate controls. Viability and toxicity were assessed by MTT assays. Proteomic analysis using mass spectrometry was conducted in the A549/EMCV bioassay to elucidate the mechanism of action, and then it was validated by Western blot.
The BL21-sIFNAR2 had a sequence identity of 83.6 % with the native form, showing variations only in terminal regions. BL21-sIFNAR2 and CHO-sIFNAR2 showed significantly higher percentage of cell viability compared to the viral control, similar to IFN-ß. Cell viability with BL21-sIFNAR2 was comparable to the cell control across all tested concentrations.
Proteomic analysis revealed an up regulation of pathways related with autophagy (macroautophagy, autophagy, pexophagy, and mitophagy) with an SQSTM1 overexpression that was then confirmed by Western Blot, especially after virus infection. However, pathways related to interferon signaling, and antiviral mechanisms mediated by IFN-stimulated genes were down-regulated.
r-sIFNAR2 exhibits significant antiviral activity regardless of the expression system used for its production and good safety profile, suggesting its use as a potential antiviral drug. Proteins related to autophagy are involved in the protection from the virus. This study highlights the biological relevance of soluble cytokine receptors as effectors so far overlooked.
[Display omitted]
•Soluble type I IFN can modulate endogenous and systemically administered IFNß, but its role is unknown.•A recombinant soluble type I IFN receptor, cloned in two systems, showed strong antiviral activity and a good safety profile.•Its mechanism of action is related to autophagy activation.•Recombinant sIFNAR2 could be of relevance for the treatment of viral diseases.</description><identifier>ISSN: 0753-3322</identifier><identifier>ISSN: 1950-6007</identifier><identifier>EISSN: 1950-6007</identifier><identifier>DOI: 10.1016/j.biopha.2024.117678</identifier><identifier>PMID: 39577364</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Antiviral activity ; Recombinant protein ; Soluble interferon beta receptor</subject><ispartof>Biomedicine & pharmacotherapy, 2024-12, Vol.181, p.117678, Article 117678</ispartof><rights>2024 The Authors</rights><rights>Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1564-2bd54e4fdbe49fc5bd41cd9b769152e01bcb01ed8f239394c059eef73db6798d3</cites><orcidid>0000-0001-9555-4847 ; 0000-0003-3452-2942</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.biopha.2024.117678$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>315,781,785,3551,27929,27930,46000</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39577364$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aliaga-Gaspar, Pablo</creatorcontrib><creatorcontrib>Brichette-Mieg, Isabel</creatorcontrib><creatorcontrib>Fernández-Arjona, MdM</creatorcontrib><creatorcontrib>Rodríguez-Bada, José Luis</creatorcontrib><creatorcontrib>López-Moreno, Yolanda</creatorcontrib><creatorcontrib>Serrano-Castro, Pedro</creatorcontrib><creatorcontrib>Fernández-Fernández, Oscar</creatorcontrib><creatorcontrib>Ciano-Petersen, Nicolás Lundahl</creatorcontrib><creatorcontrib>Oliver-Martos, Begoña</creatorcontrib><title>Recombinant soluble type I interferon receptor exerts antiviral activity by inducing proteins related to autophagy</title><title>Biomedicine & pharmacotherapy</title><addtitle>Biomed Pharmacother</addtitle><description>The soluble type I IFN receptor (sIFNAR2) is produced by alternative splicing and is present in body fluids. Although it can modulate IFN-ß activity, its biological role remains unknown.
An in-silico study was conducted to compare the structure of recombinant human soluble IFNAR2 (r-sIFNAR2) with its native form. The antiviral activity of r-sIFNAR2, produced in BL21-bacteria and CHO cells, was tested using a cytopathic effect assay including appropriate controls. Viability and toxicity were assessed by MTT assays. Proteomic analysis using mass spectrometry was conducted in the A549/EMCV bioassay to elucidate the mechanism of action, and then it was validated by Western blot.
The BL21-sIFNAR2 had a sequence identity of 83.6 % with the native form, showing variations only in terminal regions. BL21-sIFNAR2 and CHO-sIFNAR2 showed significantly higher percentage of cell viability compared to the viral control, similar to IFN-ß. Cell viability with BL21-sIFNAR2 was comparable to the cell control across all tested concentrations.
Proteomic analysis revealed an up regulation of pathways related with autophagy (macroautophagy, autophagy, pexophagy, and mitophagy) with an SQSTM1 overexpression that was then confirmed by Western Blot, especially after virus infection. However, pathways related to interferon signaling, and antiviral mechanisms mediated by IFN-stimulated genes were down-regulated.
r-sIFNAR2 exhibits significant antiviral activity regardless of the expression system used for its production and good safety profile, suggesting its use as a potential antiviral drug. Proteins related to autophagy are involved in the protection from the virus. This study highlights the biological relevance of soluble cytokine receptors as effectors so far overlooked.
[Display omitted]
•Soluble type I IFN can modulate endogenous and systemically administered IFNß, but its role is unknown.•A recombinant soluble type I IFN receptor, cloned in two systems, showed strong antiviral activity and a good safety profile.•Its mechanism of action is related to autophagy activation.•Recombinant sIFNAR2 could be of relevance for the treatment of viral diseases.</description><subject>Antiviral activity</subject><subject>Recombinant protein</subject><subject>Soluble interferon beta receptor</subject><issn>0753-3322</issn><issn>1950-6007</issn><issn>1950-6007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kEtv1DAURi1ERYfCP0DISzYZ7Pg13iChipZKlZBQWVt-3BSPMnGwnYr8ezxKYcnq3sX57uMg9I6SPSVUfjzuXUzzT7vvSc_3lCqpDi_QjmpBOkmIeol2RAnWMdb3l-h1KUdCiJDs8ApdMi2UYpLvUP4OPp1cnOxUcUnj4kbAdZ0B3-E4VcgD5DThDB7mmjKG35BrwY2OTzHbEVt_7uqK3doCYfFxesRzThXiVFputBUCrgnbpZ7PfVzfoIvBjgXePtcr9OPmy8P11-7-2-3d9ef7zlMhede7IDjwITjgevDCBU590E5JTUUPhDrvCIVwGHqmmeaeCA0wKBacVPoQ2BX6sM1t1_xaoFRzisXDONoJ0lIMo6ynnEgpG8o31OdUSobBzDmebF4NJeZs2xzNZtucbZvNdou9f96wuBOEf6G_ehvwaQOg_fkUIZviI0weQmxGqwkp_n_DH18dlYI</recordid><startdate>202412</startdate><enddate>202412</enddate><creator>Aliaga-Gaspar, Pablo</creator><creator>Brichette-Mieg, Isabel</creator><creator>Fernández-Arjona, MdM</creator><creator>Rodríguez-Bada, José Luis</creator><creator>López-Moreno, Yolanda</creator><creator>Serrano-Castro, Pedro</creator><creator>Fernández-Fernández, Oscar</creator><creator>Ciano-Petersen, Nicolás Lundahl</creator><creator>Oliver-Martos, Begoña</creator><general>Elsevier Masson SAS</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9555-4847</orcidid><orcidid>https://orcid.org/0000-0003-3452-2942</orcidid></search><sort><creationdate>202412</creationdate><title>Recombinant soluble type I interferon receptor exerts antiviral activity by inducing proteins related to autophagy</title><author>Aliaga-Gaspar, Pablo ; Brichette-Mieg, Isabel ; Fernández-Arjona, MdM ; Rodríguez-Bada, José Luis ; López-Moreno, Yolanda ; Serrano-Castro, Pedro ; Fernández-Fernández, Oscar ; Ciano-Petersen, Nicolás Lundahl ; Oliver-Martos, Begoña</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1564-2bd54e4fdbe49fc5bd41cd9b769152e01bcb01ed8f239394c059eef73db6798d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antiviral activity</topic><topic>Recombinant protein</topic><topic>Soluble interferon beta receptor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aliaga-Gaspar, Pablo</creatorcontrib><creatorcontrib>Brichette-Mieg, Isabel</creatorcontrib><creatorcontrib>Fernández-Arjona, MdM</creatorcontrib><creatorcontrib>Rodríguez-Bada, José Luis</creatorcontrib><creatorcontrib>López-Moreno, Yolanda</creatorcontrib><creatorcontrib>Serrano-Castro, Pedro</creatorcontrib><creatorcontrib>Fernández-Fernández, Oscar</creatorcontrib><creatorcontrib>Ciano-Petersen, Nicolás Lundahl</creatorcontrib><creatorcontrib>Oliver-Martos, Begoña</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biomedicine & pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aliaga-Gaspar, Pablo</au><au>Brichette-Mieg, Isabel</au><au>Fernández-Arjona, MdM</au><au>Rodríguez-Bada, José Luis</au><au>López-Moreno, Yolanda</au><au>Serrano-Castro, Pedro</au><au>Fernández-Fernández, Oscar</au><au>Ciano-Petersen, Nicolás Lundahl</au><au>Oliver-Martos, Begoña</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recombinant soluble type I interferon receptor exerts antiviral activity by inducing proteins related to autophagy</atitle><jtitle>Biomedicine & pharmacotherapy</jtitle><addtitle>Biomed Pharmacother</addtitle><date>2024-12</date><risdate>2024</risdate><volume>181</volume><spage>117678</spage><pages>117678-</pages><artnum>117678</artnum><issn>0753-3322</issn><issn>1950-6007</issn><eissn>1950-6007</eissn><abstract>The soluble type I IFN receptor (sIFNAR2) is produced by alternative splicing and is present in body fluids. Although it can modulate IFN-ß activity, its biological role remains unknown.
An in-silico study was conducted to compare the structure of recombinant human soluble IFNAR2 (r-sIFNAR2) with its native form. The antiviral activity of r-sIFNAR2, produced in BL21-bacteria and CHO cells, was tested using a cytopathic effect assay including appropriate controls. Viability and toxicity were assessed by MTT assays. Proteomic analysis using mass spectrometry was conducted in the A549/EMCV bioassay to elucidate the mechanism of action, and then it was validated by Western blot.
The BL21-sIFNAR2 had a sequence identity of 83.6 % with the native form, showing variations only in terminal regions. BL21-sIFNAR2 and CHO-sIFNAR2 showed significantly higher percentage of cell viability compared to the viral control, similar to IFN-ß. Cell viability with BL21-sIFNAR2 was comparable to the cell control across all tested concentrations.
Proteomic analysis revealed an up regulation of pathways related with autophagy (macroautophagy, autophagy, pexophagy, and mitophagy) with an SQSTM1 overexpression that was then confirmed by Western Blot, especially after virus infection. However, pathways related to interferon signaling, and antiviral mechanisms mediated by IFN-stimulated genes were down-regulated.
r-sIFNAR2 exhibits significant antiviral activity regardless of the expression system used for its production and good safety profile, suggesting its use as a potential antiviral drug. Proteins related to autophagy are involved in the protection from the virus. This study highlights the biological relevance of soluble cytokine receptors as effectors so far overlooked.
[Display omitted]
•Soluble type I IFN can modulate endogenous and systemically administered IFNß, but its role is unknown.•A recombinant soluble type I IFN receptor, cloned in two systems, showed strong antiviral activity and a good safety profile.•Its mechanism of action is related to autophagy activation.•Recombinant sIFNAR2 could be of relevance for the treatment of viral diseases.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>39577364</pmid><doi>10.1016/j.biopha.2024.117678</doi><orcidid>https://orcid.org/0000-0001-9555-4847</orcidid><orcidid>https://orcid.org/0000-0003-3452-2942</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0753-3322 |
ispartof | Biomedicine & pharmacotherapy, 2024-12, Vol.181, p.117678, Article 117678 |
issn | 0753-3322 1950-6007 1950-6007 |
language | eng |
recordid | cdi_proquest_miscellaneous_3132140666 |
source | Access via ScienceDirect (Elsevier); EZB-FREE-00999 freely available EZB journals |
subjects | Antiviral activity Recombinant protein Soluble interferon beta receptor |
title | Recombinant soluble type I interferon receptor exerts antiviral activity by inducing proteins related to autophagy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T21%3A27%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recombinant%20soluble%20type%20I%20interferon%20receptor%20exerts%20antiviral%20activity%20by%20inducing%20proteins%20related%20to%20autophagy&rft.jtitle=Biomedicine%20&%20pharmacotherapy&rft.au=Aliaga-Gaspar,%20Pablo&rft.date=2024-12&rft.volume=181&rft.spage=117678&rft.pages=117678-&rft.artnum=117678&rft.issn=0753-3322&rft.eissn=1950-6007&rft_id=info:doi/10.1016/j.biopha.2024.117678&rft_dat=%3Cproquest_cross%3E3132140666%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3132140666&rft_id=info:pmid/39577364&rft_els_id=S0753332224015646&rfr_iscdi=true |